Pharvaris N.V. (NASDAQ:PHVS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Pharvaris N.V. (NASDAQ:PHVS) has received a consensus rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $41.60.

Several analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Pharvaris in a research report on Tuesday, March 3rd. Wall Street Zen lowered shares of Pharvaris from a “hold” rating to a “sell” rating in a research report on Sunday. Finally, Royal Bank Of Canada lowered their price target on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research report on Monday.

Pharvaris Stock Down 0.7%

Shares of NASDAQ PHVS opened at $28.37 on Tuesday. The company’s 50-day simple moving average is $27.07 and its 200-day simple moving average is $25.47. Pharvaris has a 52-week low of $11.51 and a 52-week high of $29.85. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -8.42 and a beta of -2.58.

Hedge Funds Weigh In On Pharvaris

A number of institutional investors and hedge funds have recently bought and sold shares of PHVS. Geode Capital Management LLC boosted its position in Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after acquiring an additional 15,769 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the last quarter. Legal & General Group Plc boosted its position in Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after acquiring an additional 1,695 shares during the last quarter. Amundi boosted its position in Pharvaris by 2,741,600.0% during the second quarter. Amundi now owns 27,417 shares of the company’s stock worth $489,000 after acquiring an additional 27,416 shares during the last quarter. Finally, HighVista Strategies LLC boosted its position in Pharvaris by 4.3% during the second quarter. HighVista Strategies LLC now owns 23,739 shares of the company’s stock worth $418,000 after acquiring an additional 971 shares during the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.